QURE should continue climbing with recent sell off from news wall street did not like regarding licensing of their hemophilia drug. Support on Weekly MA found, MACD cross and RSI bullish divergence.
Phase 3 results should likely come out sometime in the future, like this quarter(?), based on company's prior reports.
Phase 3 results should likely come out sometime in the future, like this quarter(?), based on company's prior reports.